The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

With two maintenance doses a year, Leqvio is the first and only FDA- approved small interfering RNA therapy for LDL-C reduction 1 Leqvio provides effective and sustained LDL-C reduction of up to ...

Leqvio is the first and only small interfering RNA (siRNA) therapy to lower LDL-C and is administered with two doses a year*. Results were presented at the American Heart Association (AHA ...

Leqvio is the first and only small interfering RNA (siRNA) therapy to lower LDL-C. It is approved in over 90 countries, including the U.S., EU, Japan and China1,5,6.

Please click here for LEQVIO full Prescribing Information. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 ©2024 Novartis 6/24 FA-11211322 ...

For Leqvio’s launch, Novartis is taking a population health-based approach at 200 large U.S. healthcare systems in an effort to identify eligible patients. Among them, at least 50 systems have ...